Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301523 | 0.83 | SCN10A (0.48) | NPC1SCN10ASCN2A | |
| SCHEMBL31301578 | 0.81 | NPC1 (0.47) | SMN1; SMN2NPC1RAB9ASCN10AMEN1 | |
| SCHEMBL31301455 | 0.79 | SCN10A (0.53) | SMN1; SMN2NPC1RAB9ASCN10ASCN2A | |
| SCHEMBL31301458 | 0.79 | SCN10A (0.54) | SCN10ASCN2ALMNA | |
| SCHEMBL31301587 | 0.77 | CTSA (0.38) | NPC1SCN10ASCN2A | |
| SCHEMBL31301298 | 0.77 | SCN10A (0.50) | SCN10ASCN2AGRM5 | |
| SCHEMBL31301502 | 0.77 | SCN10A (0.56) | SCN10ASCN2A | |
| SCHEMBL31301527 | 0.76 | SCN10A (0.46) | SCN10ASCN2ALMNA | |
| SCHEMBL31301643 | 0.76 | ABL1 (0.56) | NPC1RAB9ASCN10ASCN2AMEN1 | |
| SCHEMBL31301529 | 0.76 | SCN10A (0.63) | SCN10ASCN2AMEN1KMT2ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | SMN1; SMN2 4264/4885NPC1 262/4885RAB9A 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.